Sichuan Goldstone Asia Pharmaceutical's (SZSE:300434) Conservative Accounting Might Explain Soft Earnings

Soft earnings didn't appear to concern Sichuan Goldstone Asia Pharmaceutical Inc.'s (SZSE:300434) shareholders over the last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

See our latest analysis for Sichuan Goldstone Asia Pharmaceutical

How Do Unusual Items Influence Profit?

For anyone who wants to understand Sichuan Goldstone Asia Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥87m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Sichuan Goldstone Asia Pharmaceutical took a rather significant hit from unusual items in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sichuan Goldstone Asia Pharmaceutical.

Our Take On Sichuan Goldstone Asia Pharmaceutical's Profit Performance

As we discussed above, we think the significant unusual expense will make Sichuan Goldstone Asia Pharmaceutical's statutory profit lower than it would otherwise have been. Based on this observation, we consider it possible that Sichuan Goldstone Asia Pharmaceutical's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 2 warning signs for Sichuan Goldstone Asia Pharmaceutical you should be aware of.

Today we've zoomed in on a single data point to better understand the nature of Sichuan Goldstone Asia Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.